NTLA5001, a T Cell Product Candidate with CRISPR-Based Targeted Insertion of a High-Avidity, Natural, WT1-Specific TCR, Shows Efficacy in <i>In Vivo</i> Models of AML and ALLEliana Ruggiero, Birgit C. Schultes, Maxwell Gabriel Foisey et al.|Blood|2020Cited by 1
Engineering antigen-driven co-stimulation and T helper cell activity into TCR-T cells with CD8-41BB fusion receptors enhances anti-tumor activityIvy Dutta, Aaron Prodeus, Justin Oh et al.|bioRxiv (Cold Spring Harbor Laboratory)|2026Cited by 0